Mizuho reaffirmed their neutral rating on shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) in a research note released on Wednesday, January 3rd, Marketbeat.com reports. Mizuho currently has a $18.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $14.00.
SCMP has been the subject of several other research reports. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a hold rating to a buy rating and set a $11.00 price objective for the company in a research report on Tuesday, October 17th. Nomura assumed coverage on shares of Sucampo Pharmaceuticals in a research report on Monday, December 18th. They issued a buy rating and a $43.00 price objective for the company. UBS Group lowered their price target on shares of Sucampo Pharmaceuticals from $19.00 to $15.00 and set a buy rating for the company in a report on Thursday, October 12th. BidaskClub raised shares of Sucampo Pharmaceuticals from a hold rating to a buy rating in a report on Tuesday, December 5th. Finally, ValuEngine raised shares of Sucampo Pharmaceuticals from a hold rating to a buy rating in a report on Friday, December 1st. Six investment analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. Sucampo Pharmaceuticals has an average rating of Buy and a consensus target price of $21.58.
Sucampo Pharmaceuticals (NASDAQ SCMP) traded down $0.35 during trading hours on Wednesday, reaching $18.05. 1,562,916 shares of the company’s stock were exchanged, compared to its average volume of 4,243,397. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.46 and a current ratio of 5.11. The stock has a market capitalization of $851.38, a P/E ratio of -5.49, a P/E/G ratio of 5.07 and a beta of 1.45. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $18.75.
In other Sucampo Pharmaceuticals news, insider Peter A. Kiener sold 50,000 shares of the firm’s stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $16.50, for a total transaction of $825,000.00. Following the completion of the transaction, the insider now directly owns 52,023 shares of the company’s stock, valued at approximately $858,379.50. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.13% of the stock is owned by company insiders.
A number of hedge funds have recently made changes to their positions in SCMP. HPM Partners LLC bought a new position in shares of Sucampo Pharmaceuticals in the 2nd quarter worth about $1,307,000. Trexquant Investment LP bought a new position in shares of Sucampo Pharmaceuticals in the 3rd quarter worth about $122,000. Nine Chapters Capital Management LLC bought a new position in shares of Sucampo Pharmaceuticals in the 3rd quarter worth about $127,000. JPMorgan Chase & Co. bought a new position in shares of Sucampo Pharmaceuticals in the 2nd quarter worth about $117,000. Finally, Aperio Group LLC bought a new position in shares of Sucampo Pharmaceuticals in the 3rd quarter worth about $137,000. 65.29% of the stock is owned by institutional investors.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with our FREE daily email newsletter.